Related Experiment Video

Updated: Aug 11, 2025

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.5K

Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects

Yijia Chen1,2, Yuxi Wang1,3,4, Jiaxing Wang5

  • 1Joint Research Institution of Altitude Health, Department of Respiratory and Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.

Journal of Medicinal Chemistry
|February 6, 2023
PubMed

Insights

Casein kinase 2 (CK2) is vital for cell functions and disease, making it a therapeutic target. Novel small-molecule inhibitors are emerging to overcome limitations of existing drugs like CX-4945.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Casein kinase 2 (CK2) is a ubiquitous serine/threonine kinase regulating critical cellular processes such as growth, apoptosis, and DNA repair.
  • Dysregulation of CK2 is implicated in cancer pathogenesis and various other diseases, highlighting its role as a therapeutic target.

Purpose of the Study:

  • To review the structure, biological functions, and disease relevance of CK2.
  • To analyze the structure-activity relationships (SAR) and binding modes of small-molecule CK2 inhibitors.
  • To discuss novel strategies and recent advancements in CK2 inhibitor development for clinical applications.

Main Methods:

  • Literature review and analysis of existing research on CK2.
  • Examination of structure-activity relationships (SAR) of small-molecule CK2 inhibitors.
  • Discussion of novel therapeutic strategies and recent advancements in the field.

Main Results:

  • CK2 plays a crucial role in numerous cellular functions and disease development.
  • Several small-molecule CK2 inhibitors have been developed, with CX-4945 being the only one in clinical trials.
  • Novel inhibitors show promise in overcoming limitations of traditional CK2-targeting drugs.

Conclusions:

  • CK2 is a significant therapeutic target due to its role in disease.
  • Understanding SAR and binding modes is key to designing effective CK2 inhibitors.
  • Emerging novel strategies offer promising avenues for developing new CK2-targeted therapies.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.8K

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.2K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.8K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
835
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K